Kenneth J. Mcgrath Purchases 64,000 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth J. Mcgrath purchased 64,000 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the acquisition, the chief financial officer now owns 371,013 shares in the company, valued at $1,168,690.95. The trade was a 20.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

OraSure Technologies Trading Up 2.3 %

Shares of NASDAQ OSUR opened at $3.13 on Friday. The stock has a fifty day moving average price of $3.78 and a 200 day moving average price of $4.01. The company has a market cap of $233.48 million, a P/E ratio of 20.87 and a beta of 0.05. OraSure Technologies, Inc. has a 12-month low of $2.68 and a 12-month high of $8.04.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, February 22nd.

Institutional Investors Weigh In On OraSure Technologies

A number of large investors have recently modified their holdings of OSUR. BNP Paribas Financial Markets lifted its position in OraSure Technologies by 27.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock worth $3,655,000 after acquiring an additional 183,191 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of OraSure Technologies by 28.5% during the third quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock valued at $1,091,000 after purchasing an additional 59,723 shares during the period. JPMorgan Chase & Co. lifted its position in shares of OraSure Technologies by 5.8% during the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock worth $3,621,000 after purchasing an additional 46,216 shares in the last quarter. Barclays PLC lifted its position in shares of OraSure Technologies by 182.6% during the third quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock worth $836,000 after purchasing an additional 126,503 shares in the last quarter. Finally, Exchange Traded Concepts LLC purchased a new position in shares of OraSure Technologies in the fourth quarter valued at $287,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.